Clinical Trial Update: Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

View source ↗

Summary

A completed real-world study evaluating Relapsing Multiple Sclerosis patients treated with ofatumumab or ocrelizumab in the Gulf region.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Status: COMPLETED